Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Respicardia, Inc., the manufacturer of the only FDA-approved active implantable device for the treatment of central sleep apnea (CSA), today...
Respicardia, Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has approved an outpatient Transitional Pass-through...
Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, today announced that the Centers...
Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, announced today that the first...
Respicardia, Inc., a private medical technology company, announced today that the company has closed a $58.5 million financing, led by ZOLL Medical...
Respicardia, Inc., a private medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) approval of its...
Respicardia®, Inc., fabricant de dispositifs implantables visant à améliorer la santé cardiovasculaire et respiratoire, a annoncé avoir remporté le...
Respicardia®, Inc., ein Entwickler implantierbarer Behandlungslösungen für die Verbesserung der respiratorischen und kardiovaskulären Gesundheit, gab ...
Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the...
Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the U.S....
Respicardia, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced it has received approval from the ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.